Abstracts tagged "Biologic-naive"

Abstract Number: 1832 • ACR Convergence 2021
Secukinumab Therapy in Biologic-naïve vs. Biologic-experienced Patients: Real-world Effectiveness, Persistence and Safety Results from the Rheumatic Diseases Portuguese Registry
Soraia Azevedo¹, Jose Tavares-Costa², Pedro Laires³, Salomé Garcia⁴, Patricia Nero⁵, Jorge Pestana⁶, Joana Martins-Martinho⁷, Ana Bento Silva⁸, Joana Rodrigues⁹, Graca Sequeira¹⁰, Emanuel Costa¹¹, Filipe Cunha Santos¹², Carolina Furtado¹³, Bernardo Santos¹⁴, Ana Raposo¹⁵, Liliana Saraiva¹⁶, Beatriz Samões¹⁷, Filipe Barcelos¹⁸, Maria José Santos⁶ and Helena Santos¹⁹, ¹Unidade Local de Saude do Alto Minho, Ponte de lima, Portugal, ²Rheumatology Department - Unidade Local de Saude do Alto Minho, Ponte de Lima, Portugal, ³Novartis Portugal / ENSP – NOVA University of Lisbon, Lisbon, Portugal, ⁴Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Porto, Portugal, ⁵CUF, TELHEIRAS, Portugal, ⁶Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, ⁷Centro Hospitalar Universitario Lisboa Norte, Lisboa, Portugal, ⁸Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal, ⁹Rheumatology Department, ULSAM, Ponte de Lima, Portugal, ¹⁰Rheumatology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal, ¹¹Hospital de Braga, Braga, Portugal, ¹²Rheumatology Department, Local Health Unit of Guarda, Guarda, Portugal, ¹³Rheumatology Department, Hospital do Divino Espírito Santo de Ponta Delgada, Ponta Delgada, Portugal, ¹⁴Rheumatology Department, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, ¹⁵Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, Portugal, ¹⁶Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ¹⁷Rheumatology Department, Centro Hospitalar Vila Nova de Gaia, Vila Nova de Gaia, Portugal, ¹⁸Instituto Português de Reumatologia, Lisbon, Portugal, ¹⁹Portuguese Institute of Rheumatology, Lisbon, Portugal
Background/Purpose: Secukinumab has demonstrated to be efficacious for both psoriatic arthritis (PsA) and ankylosing spondylitis (AS): PASI, ACR and ASAS magnitudes of response have generally…